Investment

#Investment #Life sciences

UK could gain £1.9bn in growth through university investment  

Almost £2 billion (£1.9bn) of economic value could be generated over the next decade if investment rises in laboratories, research facilities, science parks and innovation districts, a new report from Lloyds suggests.   The report, Innovation Foundations, states that underinvestment in university estates is limiting private sector R&D, spinout creation and local economic growth. It states that the UK… Read More

#News

#Investment #Life sciences #Venture funds

Sofinnova Partners expands expertise with new partner  

Venture capital firm Sofinnova Partners has appointed a deep pharma and drug development expert as Partner, the company has announced.  David Evans is a physician-scientist with deep pharma and drug development expertise. He joins from the Roche Venture Fund, where he previously served as Senior Investment Director. There, he built a… Read More

#News

GBP pound sterling funding
#Antibodies #Drug discovery #Investment

Alchemab receives £25 million from British Business Bank 

Biotech Alchemab Therapeutics has extended its series A financing with a £25 million ($34 million) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date.   The company says the funding will enable it to build its clinical pipeline and grow its antibody dataset to more… Read More

#News

#Drug discovery #Drug Discovery Innovators & Investors #Events #Innovation #Innovators & Investors #Investment

Introducing the Drug Discovery Innovators & Investors Event Series

We’re excited to announce the launch of Drug Discovery Innovators & Investors (DDII) – a new event series from Drug Discovery World. The three-part global event series focuses on technology, innovation, and investment in early-stage drug discovery. Bringing together senior executives, R&D leaders, lab managers, and decision-makers from pharma and… Read More

#Editor's Choice #News

#Cell therapy #Europe #Investment

Cellares extends funding for cell therapy manufacturing 

Cellares has raised $327 million for its cell therapy infrastructure project.  Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners.  The investment is set to support the next… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Investment #Life sciences #Oncology

Bead BioPharma emerges from stealth with novel drug platform 

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform.  The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology.  Bead BioPharma is focused on antibody-drug conjugates (ADCs), a… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Investment

Ona raises $86.6m to advance cancer-targeting ADCs 

Ona Therapeutics has announced it has raised $86.6 million to advance its first-in-class antibody-drug conjugates (ADCs) into clinical development.  The biopharmaceutical company raised the money in a Series B financing round, co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys. … Read More

#Business & Investment #News

A strip of 8 PCR tubes on the thermal cycler
#Investment #PCR

Countable Labs raises $26m to commercialise PCR technology 

Countable Labs has said it has raised $26 million to accelerate its clinical product development and the global commercialisation of Countable PCR.  The biotechnology company raised the capital in an oversubscribed financing round, which will allow it to leverage capabilities to support cell and gene therapy, minimal residual… Read More

#News

#Equity finance #Investment #Neuroscience

MindMaze Therapeutics raises CHF 8m in equity financing 

Neurotherapeutics company MindMaze Therapeutics has announced it has raised CHF 8 million (€8.7 million) in strategic equity financing.  The financing has been raised through a definitive agreement with Neuro.io, which will acquire a strategic equity position in the company.  MindMaze Therapeutics says it will use the funds raised to support… Read More

#News

#Biotech #Investment #T cell engagers

Cytospire raises £61m to advance T cell engager pipeline 

UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced.  The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme,… Read More

#Business & Investment #News

#Biotech #Investment #Switzerland

Swiss biotech saw record revenues in 2025, report says 

The Swiss biotech industry recorded its highest ever revenues in 2025, a new report shows.  The 2026 Swiss Biotech Report says the industry saw record revenues of CHF 7.5 billion (€8.2 billion) in 2025, up from CHF 7.2 billion (€7.9 billion) in 2024.  Employment in… Read More

#News

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts